Item 7.01 Regulation FD Disclosure.

On February 6, 2023, Pulmatrix, Inc. (the "Company") issued a press release, attached hereto as Exhibit 99.1, announcing the first patient dosed in a Phase 2b trial evaluating safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

Exhibit
Number    Description

99.1        Press Release, dated February 6, 2023 (furnished herewith pursuant to
          Item 7.01)
104       Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses